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Abstract
Background: Prostate-specific antigen (PSA) screening, although common, has recently been called into question. To find
prostate cancer (PCa) diagnostic biomarkers that can make up for the defects of PSA, we compared the secretomes of
several benign and PCa cell lines, selected candidate molecules, and then confirmed their clinical value.
Methodology/Principal Findings: We first identified extracellular proteins by two-dimensional gel electrophoresis (2-DE)
coupled with liquid chromatography-tandem mass spectrometry (LC-MS/MS) identification. We then validated the secreted
proteins on a cellular level, and finally determined whether they could be used as PCa diagnostic biomarkers using prostate
tissue and serum specimens of Chinese volunteers by immunohistostaining and sandwich ELISA. We obtained credible
extracellular protein 2-DE graphs of prostate cell lines. The 5 spots that showed superior repeatability were selected for LC-
MS/MS analysis, which identified seven candidate molecules. One of the candidate molecules, spondin-2 (SPON2), was only
expressed in the conditioned media (CM) of androgen receptor (AR) positive PCa cell lines. Using tissue microarray by
immunohistostaining, we found SPON2 to be over-expressed in PCa. SPON2 staining was more intense in Gleason score
sum 7–8 and in PCa patients with metastasis. By receiver operator characteristic (ROC) curve analysis, we found that the
serum SPON2 level was elevated in PCa patients, showing sensitivity and specificity suitable for diagnostic use. We also
found that SPON2 could be used to identify PCa patients with serum PSA levels no higher than 10 ng/ml from healthy
elderly men.
Conclusion/Significance: SPON2 is a new serum and histological diagnostic biomarker for PCa. It can avoid some of the
problems of PSA testing and was here found to offer relatively high sensitivity and specificity relative to PSA.
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Introduction
In the U.S., prostate cancer (PCa) alone accounts for 28% of all
cancer cases in men [1]. Prostate-specific antigen (PSA), an
androgen-regulated serine protease produced by both normal
prostate epithelial cells and prostate cancer (PCa), is the most
commonly used serum biomarker for PCa [2]. The determination
of serum PSA levels and digital rectal examinations (DRE) are
recommended by the majority of clinical guidelines for early
detection of prostate cancer [3].
Although PSA screening has many advantages, it has been
questioned in recent years. One of the major disadvantages of PSA
is that it cannot be used to monitor healthy men for prostate
cancer with simultaneous high sensitivity and high specificity [4].
The level of total PSA is elevated in acute prostatitis and benign
prostatic hyperplasia (BPH) [5,6]. Among men with slightly
elevated PSA levels at 4–10 ng/ml, four men have to undergo
biopsy to detect one man with PCa [3]. PSA screening may also
cause misdiagnosis and prevent patients from seeking therapy in a
timely manner. Thompson et al. discovered that among 2950
elderly men with a PSA level of 4.0 ng per milliliter or less, PCa
was diagnosed in 449; 67 of them had a Gleason score sum of 7 or
higher [7]. These examples highlight the urgency of discovering
novel prostate-cancer-specific serum biomarkers that can discern
life-threatening PCas, as well as PCas with serum PSA levels
#10 ng/ml.
Here we compared the concentrated condition medium (CM)
protein two-dimensional gel electrophoresis (2-DE) graph of BPH-
1 (a BPH epithelial cell line, and its cytokeratin expression profile
is consistent with a prostatic luminal epithelial cell [8]), LNCaP,
and C4-2 (a derivative cell line of LNCaP that is androgen-
independent, highly tumorigenic, and metastatic [9]). About 400
silver-staining-positive spots were obtained per 2-DE gel. After the
elimination of background noise, standardization, and match
analysis, we chose 5 spots whose differences appeared stable for
LC-MS/MS identification. Seven candidate molecules were
identified. One of the candidate molecules, SPON2, was only
expressed in the CM of androgen-receptor-positive (AR–positive)
PCa cell lines.
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37225By tissue microarray immunohistochemical staining, we found
that SPON2 expression in PCa tissues was higher than in normal
prostate and BPH tissues. SPON2 expression was higher in PCa
tissues with Gleason scores of 7–8 and in those from metastatic
patients. Using a sandwich ELISA protocol, we compared 13
healthy, elderly men to 70 PCa patients and found that the serum
SPON2 level was elevated in the latter. The area under the
receiver operator characteristic (ROC) curve (AUC) of serum
SPON2 was larger than 0.90, indicating a higher diagnostic value.
The ROC curve also suggested that serum SPON2 concentrations
of about 8 ng/mL gave the highest accuracy and best positive and
negative predictive values–97.2% and 100%, respectively, as well
as best sensitivity (100%) and specificity (84.6%). Comparing the
ROC curves of serum SPON2 and PSA of PCa patients with PSA
levels below 10 ng/mL to healthy controls, SPON2 was found to
differentiate PCa patients with serum PSA#10 ng/ml from
healthy, elderly aged men, while PSA could not.
Results
Screening of candidate molecules in CM of PCa cell lines
Eighty micrograms of concentrated and purified extracellular
proteins in CM of BPH-1, LNCaP, and C4-2 were separated by 2-
DE. Scanned images of silver-stained 2-DE gels are shown in
Figure 1A–C. The results were analyzed using PDQuest software,
revealing about 400 protein spots per gel, of which five were up-
regulated in CM from LNCaP and C4-2 cells in three independent
repeated trials (The corresponding regions are enlarged and shown
in Figure 1D.). The five differentially expressed protein spots were
further detected by LC-MS/MS, and seven candidate molecules
were identified: triosephosphate isomerase 1 (TPI1), thrombos-
pondin 1 (THBS1), phosphoglycerate mutase 1 (PGAM1),
spondin-2 (SPON2), syndecan binding protein 1 (ST1), peroxir-
edoxin 1 (PRDX1), and nucleophosmin (NPM1). As shown in
Table 1, all seven proteins had high sequence coverage and
Mascot scores. The probability-based Mowse score of each spot
and matched peptides of each protein are shown in Figure S1. We
were unable to determine which of the four candidate proteins
identified in Spot 1 (Table 1) was up-regulated in CM from
LNCaP and C4-2 cells. Further exploration of each protein, on
cellular level, is merited.
Expression of SPON2 was up-regulated in CM of AR-
positive PCa cell lines
First, five of seven candidate molecules were identified by RT-
PCR in six prostate cell lines, in cervical cancer cell line Hela, and
in breast cancer cell line MCF-7. One of the candidate molecules,
SPON2, in accordance with the tendency of the selected 2-DE
spot, was up-regulated in CM of LNCaP and C4-2 relative to
BPH-1(Figure 2A). RT-PCR results suggested that SPON2
mRNA was highly expressed in androgen-receptor-positive PCa
cell lines. Western blots of cell lysates (CL) and CM protein also
demonstrated that SPON2 was only positive in the CM of LNCaP
and C4-2 (Figure 2B). This was consistent with the results of semi-
quantitative RT-PCR. We established a method for SPON2
sandwich ELISA quantitation. By plotting the log of the corrected
optical density readings (x-axis) versus the log of their correspond-
ing SPON2 concentration (y-axis), a linear equation was fitted as
Figure 2C. SPON2, in 10 mg concentrated extracellular protein in
CM from different prostate cell lines, was quantitated by sandwich
ELISA, as shown in Figure 2D. We found, in accordance with the
results of semi-quantitative RT-PCR, that SPON2 was only
expressed in the CM of AR-positive PCa cell lines LNCaP, C4-2,
and C4-2B. We selected SPON2 as a candidate for histological
and serological testing.
Immunohistostaining suggested SPON2 was a potential
biomarker for PCa
Two sections from one tissue block separately stained with
hematoxylin & eosin (HE) and with SPON2 are shown in Figure 3.
HE staining is shown as the control. The expression of SPON2 in
different cases is also shown in Figure 3A–D. The mean integrated
optical density (IOD) for SPON2 protein expression (immunohis-
tochemistry) in 73 specimens containing 10 normal prostate tissue
samples, 19 BPH tissue samples, 44 PCa tissue samples with
different Gleason scores, and samples of PCa tissue both with and
without metastasis were calculated using Image-Pro Plus 6.0
software (Table S1).
SPON2 IOD sums were represented by median (interquartile
range), e.g. M (QR), and statistically tested by SNK grouping test
(q test). We found that SPON2 expression was higher in PCa than
in either normal or BPH tissue samples, to a statistically significant
extent (Figure 3A).
The PCa specimens were divided into three groups by Gleason
score sum: Gleason score sums no more than 6, Gleason score
sums 7 or 8, and Gleason score sum 9 or 10. We found SPON2
expression in the group sums 7 or 8 to be higher than in either the
normal or BPH tissue samples, to a statistically significant degree.
Specimens that were sums no more than 6 showed significantly
more expression than BPH (Figure 3B).
PCa specimens were also divided into two groups based on
patients’ status: specimens from patients without metastasis (M0)
and specimens from patients with metastasis (M1). We found that
SPON2 expression was significantly higher in group M1 than in
the normal or BPH tissues (Figure 3C).
Serum SPON2 levels were elevated in PCa patients
The serum SPON2 levels of 13 healthy, elderly men and 70
PCa patients (Table S2) were quantitated using SPON2 sandwich
ELISA with the above-mentioned standard curve (Figure 2C). We
found serum SPON2 level of PCa patients (95% confidence
interval, 95%CI=27.55–52.69) was significantly higher than that
of healthy, elderly men (95%CI=0–7.78) (P,0.001, Figure 4A).
Sensitivity, specificity, AUC, and all cutoff values of SPON2 levels
were determined using ROC analysis. SPON2 cutoff values of 3,
6, 8, 10, 15, and 20 ng/mL yielded sensitivities of 100%, 100%,
100%, 94.3%, 75.7%, and 54.3% and specificities of 69.2%,
76.9%, 84.6%, 84.6%, 84.6%, and 100%, respectively. When
8 ng/ml was chosen as the cutoff value, the sum of sensitivity
(100%) and specificity (84.6%) was the highest, and the positive
and negative predictive values were 97.2% and 100%, respectively
(AUC=0.942, SE=0.039, 95% CI=0.866–1.019, P,0.001).
The 70 PCa patients were divided into two groups, 9 with
serum PSA level #0 ng/mL and 61 with serum PSA level
.10 ng/mL. The serum SPON2 and PSA levels of these two
groups of patients were compared to a group of healthy, elderly
men (Table 2). The serum SPON2 of PCa with PSA#10 ng/ml
and .10 ng/ml were significantly higher than that of healthy
controls (P=0.0013 and P,0.001). As expected, serum PSA levels
of PCa.10 ng/ml were significantly higher than those of healthy
controls, while PSA#10 ng/ml did not show any statistical
significance against healthy controls (P=0.2852). ROC analysis
for serum SPON2 and PSA of PCa patients with PSA levels
#10 ng/mL and healthy controls were also conducted (Figure 4C).
The AUCs were 0.915 (SE=0.063, 95%CI=0.790–1.039,
P=0.001) and 0.645 (SE=0.146, 95%CI=0.359–0.931,
P=0.256), respectively. For the serum SPON2 levels of these
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sensitivity of 100% and specificity of 84.6%. For PSA, at the
recommended 4 ng/ml cutoff value, sensitivity and specificity
were only 44.4% and 92.3%, respectively.
Discussion
All the proteins secreted by viable cells constitute an organism’s
‘‘secretome’’. Some secreted proteins are released into the blood,
so secretome research may help to reveal novel candidate serum
biomarkers with potential clinical significance [10].
Gross et al. compared secretome protein profiles in medium
from LNCaP cells stimulated with androgens, estrogen, and
interleukin-6 and discovered that b2-microglobulin (B2M) became
specifically up-regulated in the condition-medium of androgen-
induced LNCaP cells [11]. Further research suggested that serum
B2M levels are elevated in patients with metastatic, androgen-
independent prostate cancer. Sardana G. performed a qualitative
proteomic analysis of CM from the PCa cell line PC3(AR)6 and
discovered a new PCa serum biomarker, Mac-2BP [12]. This
suggests that the analysis of CM may reveal more novel, valuable
PCa serum biomarkers.
SPON2 (spondin-2, Mindin, DIL-1) belongs to the F-spondin
family of secreted extracellular matrix proteins [13]. SPON2 is
differentially expressed in cancerous and non-cancerous lung cells
[14]. It is essential to the initiation of the innate immune response
and represents a unique pattern-recognition molecule in the
extracellular matrix for microbial pathogens [15]. Another study
reported that it serves as an integrin ligand and is critical for
inflammatory cell recruitment [16]. Recent research has suggested
that R-spondin family members regulate the Wnt pathway by a
common mechanism and that R-spondin2 is a secreted activator
of Wnt/b-catenin signaling [17,18]. Iris Simon discovered that
SPON2 is up-regulated in sera of ovarian cancer patients [19].
Renate Parry’s research suggested that SPON2 mRNA is
expressed predominantly in the prostate (both tumor and normal
samples), and at significantly lower levels in other tissues [20].
Romanuik’s analysis demonstrated that SPON2 is enriched in
human prostate cancer cell lines over in other human cancer cell
lines [21]. Using LNCaP tumor xenograft nude mice models,
SPON2 was used for antibody-based radiotherapy of prostate
cancer [20]. Sardana et al analyzed the CM proteomics from the
PC3, LNCaP, and 22Rv1 prostate cancer cell lines by two-
dimensional chromatography and tandem mass spectrometry,
obtained four candidate biomarkers including spondin-2, and
discovered that its expression level in sera showed a significant
difference between patients with or without prostate cancer [22].
All these results suggest SPON2 may be a new biomarker for PCa.
A prostate tissue microarray was immunohistostained with anti-
SPON2 antibody. We found that the SPON2 staining intensity of
PCa was significantly more intense than that of healthy, elderly
men and BPH patients. SPON2 staining was more intense in
sample with Gleason score sums 7–8 and in samples from
metastatic PCa patients.
We used a sandwich ELISA protocol to compare serum SPON2
levels of 13 healthy controls and 70 PCa patients using Willcoxon
2 sample testing and to assess the diagnostic efficiency using ROC
curves. We found that the serum SPON2 level was significantly
elevated in PCa patients. The area under the ROC curve was
larger than 0.90, indicating accuracy. Serum SPON2 concentra-
tions ,8 ng/mL gave the best positive and negative predictive
values, 97.2% and 100%, respectively, the best sensitivity (100%),
and the best specificity (84.6%).
By Willcoxon 2 sample testing, we also found that serum
SPON2 levels of PCa patients whose serum PSA level was at or
below 10 ng/mL was significantly higher than that of healthy
controls, but their serum PSA levels were not. Based on the AUCs
and their 95% CI and P values, ROC curves for serum SPON2
and PSA suggested that SPON2 can differentiate PCa patients
with serum PSA#10 ng/ml from healthy, elderly controls and
that PSA cannot.
Regrettably we did not collect any sera from BPH, acute
prostatitis, or prostatic intraepithelial neoplasia candidate patients,
partly because of patients’ preferences and partly because of the
difficulties of excluding concomitant PCa without biopsy. Further
studies on these patients are needed, but combining the results
with the above-mentioned immunohistostaining results, we believe
that SPON2 shows potentials as a more PCa-specific serum
biomarker than PSA.
Based on these results, we concluded that SPON2 was a new
serum and histological diagnostic biomarker for prostate cancer,
showing independent diagnostic value and an ability to avoid some
of the problems inherent in PSA.
Materials and Methods
Ethics Statement
Serum samples were collected before any clinical treatment
from the Cancer Hospital of the Chinese Academy of Medical
Science (Table S2). All volunteers were native Chinese, xantho-
derm. Seventy PCa inpatients from this hospital also volunteered.
Their diagnoses were verified by biopsy, and all gave their written
informed consent. Thirteen healthy, elderly men (also with written
informed consent) volunteered to serve as the control group. Only
men found by DRE and B-mode ultrasound to have no prostate
legions were allowed to serve as controls. The protocols for
collection and analysis of the samples were approved by the
National Cancer Center (NCC) Ethics Committee of China in
accordance with the current revision of the Helsinki Declaration.
Samples were stored at 280uC until analysis. The serum PSA
levels of the patients were quantitated using a Roche Elecsys
automatic electrochemiluminescence immunoassay as well as its
supplementary PSA electrochemiluminescence detecting kit
(Roche Diagnostics, GmbH). Corresponding standard curve
preparation and serum PSA quantitation strictly obeyed the
operation protocol offered by Roche.
Cell culture
Human prostate carcinoma cell lines, LNCaP, C4-2, C4-2B
(also derivative cell line of LNCaP that is androgen-independent,
highly tumorigenic, and metastatic [9]), PC3, and DU145, which
had been used in reference [23] were obtained as gifts from Leland
W. K. Chung (Cedars Sinai Medical Center, Los Angeles, CA,
U.S.); cell line BPH-1 was a gift from J. Zhang (Nankai University,
Tianjin, China, PR.) and had been used in reference [24]. Breast
cancer cell line MCF-7 and cervical cancer cell line HeLa were
Figure 1. Two-dimensional gel electrophoresis profiles of condition media from BPH-1, LNCaP, and C4-2 cells. Two-dimensional
electrophoregram of condition media from (A) BPH-1, (B) LNCaP, and (C) C4-2 cells are shown. (D) Enlarged corresponding areas of selected protein
spots from these cell lines are also shown. Proteins in condition media of all cells were resolved by two-dimensional gel electrophoresis and silver-
stained. White arrows indicate the differential spots.
doi:10.1371/journal.pone.0037225.g001
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grown in RPMI 1640 medium (Gibco, Paisley, U.K.) supplement-
ed with 10% fetal bovine serum.
Protein separation by 2-DE and silver staining
Collection, assay, concentration, and purification of proteins
from CM were performed as in reference [25]. Precipitated
protein samples (80 ug) were loaded for 2-DE protein separation
using 7 cm ReadyStrip IPG Strips (pH 3–10, linear) in strict
accordance with the product manual 2-D Electrophoresis for
Proteomics (Bio-Rad), Each experiment was repeated independently
three times. The gels were silver-stained as in reference [26].
Scanning was carried out with a flatbed scanner and processed
with PDQuest software (Bio-Rad). Each gel was normalized by
total valid spot intensity, and differentially expressed spots were
defined as spots with more than a two fold difference between cell
lines.
In gel digestion, LC-MS/MS, and database querying
In gel digestion, LC-MS/MS, and database querying are
routine operations in the instrument center of our institute.
Protocols are listed in Text S1.
Semi-quantitative reverse transcription PCR (RT-PCR)
Total RNA was purified using Trizol Reagent (Invitrogen Life
Technologies). First-strand cDNA was generated using the First
Strand Synthesis System (TOYOBO, Japan) according to the
manufacturer’s instructions. Primers for semi-quantitative RT-
PCR are shown in Table S3.
Western blot
Extracellular proteins in CM and holoproteins in CL were
harvested and assayed as described in reference [25]. Western blot
analyses were also performed as described, except we used goat
anti-human SPON2 (R&D Systems), goat anti-human PSA, and
rabbit anti-human b-actin (Santa Cruz Biotechnology, Inc.)
antibodies [25].
Immunohistochemical staining
A human prostate tissue microarray was purchased from
Chaoying Biotechnology Co., China, and all its included subjects
were native Chinese. Tissue microarray was immunohistochem-
ically stained with goat anti-SPON2 antibody (R&D Systems, Inc.,
1:50 dilution) as recommended by Zhongshan Goldenbridge
Biotechnology, Co., China.
Five randomly selected 4006 visual fields per specimen were
photographed and the SPON2 IOD sum of each field was
calculated using Image-Pro Plus 6.0 software (Media Cybernetics,
Inc.). The IOD Sum of each specimen, i.e. the arithmetic mean of
IOD sums of five randomly selected fields, was reflective of
SPON2 expression level in the prostate tissue. Prostate cancer
tissues were graded according to the Gleason scoring and TNM
staging systems. Tumor details were extracted from medical
records by Chaoying Biotechnology Co. (Table S1).
Establishment of SPON2 sandwich ELISA quantitation
protocol
A 96-well polystyrene microplate was coated with goat anti-
human SPON2 polyclonal antibody (R&D Systems, Inc.) at 4uC
Figure 2. Expression of spondin-2 (SPON2) in the condition media of androgen-receptor-positive prostate cancer cell lines. (A) Semi-
quantitative reverse transcription PCR analysis of five candidate molecules. (B) Western blot analysis of cell lysates and condition media protein with
anti- SPON2 and anti- prostate-specific antigen (PSA) antibody. (C) Standard curve for SPON2 sandwich ELISA. (D) SPON2 quantitation in 10 mg
extracellular protein in condition media of different prostate cell lines.
doi:10.1371/journal.pone.0037225.g002
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PLoS ONE | www.plosone.org 6 May 2012 | Volume 7 | Issue 5 | e37225Figure 3. Spondin-2 (SPON2) immunohistostaining analysis of prostate tissue microarray. SPON2 integral optical density (IOD) sums of
all prostate cancer patients (A), group Gleason score sum 7–8 (B) and metastasis (C) were all higher than those of both normal and benign prostatic
hyperplasia (SNK* represents SNK grouping test results and groups with the same letter are not significantly different; GS** represents Gleason score
sum; M*** represents metastasis status.). Same regions of same samples staining with hematoxylin and eosin (HE) and SPON2 separately were shown
in (D).
doi:10.1371/journal.pone.0037225.g003
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tween 20 (v/v)) and blocked (blocking buffer: PBST with 1%
bovine serum albumin (BSA, v/v)). SPON2 recombinant protein
(Abnova, Inc.) was diluted with blocking buffer to specific
concentrations: 100, 50, 25, 12.5, 6.25, 3.13, and 1.57 ng/mL.
These were used as standards. Blocking buffer served as the zero
standard (0 ng/mL). The blocking buffer was discarded, and each
standard was added to the microplate at 100 ml per well with two
repetitions. The plate was then incubated. After three washes with
PBST, mouse anti-human SPON2 monoclonal antibody (Abnova,
Inc.) diluted with blocking buffer was added to the microplate and
incubated. After three washes with PBST, diluted corresponding
secondary antibody was added and incubated. After three washes
with PBST, soluble TMB single-substrate solutions were added to
each well and incubated for 15 minutes. The optical density
readings at 570 nm were subtracted from the readings at 450 nm.
The arithmetic mean of two zero-standard wells was subtracted
from that of the two repeated wells. These values served as the
corrected optical density readings of their corresponding SPON2
concentrations. By plotting the log of corrected optical density
readings (x-axis) versus the log of their corresponding SPON2
concentrations (y-axis), a linear equation was fitted as the standard
Figure 4. Serum concentration testing of spondin-2 (SPON2). (A) SPON2 in 70 prostate cancer patients and 13 healthy elderly men were
compared. Willcoxon 2 sample testing was used to determine the significance of the differences between two groups. (B) A SPON2 receiver operator
characteristic (ROC) curve for above cases is shown. (C) SPON2 and prostate-specific antigen (PSA) ROC curves for prostate cancer patients with serum
PSA#10 ng/mL and healthy elderly men are shown.
doi:10.1371/journal.pone.0037225.g004
Table 2. Quantitating serum SPON2 levels in healthy and
prostate cancer (PCa) patients with different levels of serum
prostate-specific antigen (PSA) by sandwich ELISA (ng/ml).
Diagnostic Conclusion
Number of
Cases
SPON2
M(QR)* PSA M(QR)
Healthy 13 0.45 (5.19) 0.40 (2.30)
PCa PSA#10 ng/ml 9 16.01 (15.06) 3.94 (5.16)
PSA.10 ng/ml 61 21.53 (27.24) 88.50 (274.78)
*: median (interquartile range).
doi:10.1371/journal.pone.0037225.t002
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Office Excel 2003.
Serum and CM SPON2 quantitation by sandwich ELISA
Sera were 1:2 diluted by blocking buffer for sampling. Blocking
buffer was used to dilute 10 mg amounts of assayed and
concentrated CM protein to a final volume of 100 ml for sampling.
Blocking buffer served as the zero standard. According to the
above-mentioned sandwich ELISA protocol, except what we used
for sampling, we subtracted the zero standard well from each well
to provide corrected optical density readings of each correspond-
ing sample. Each log of corrected reading as x and substituted into
above-mentioned standard curve, for serum samples, 3610
y ng/
mL was taken to be the SPON2 concentration of the correspond-
ing serum. For CM of different cell lines, 0.1610
y ng was the
SPON2 content in 10 mg concentrated extracellular protein in
CM.
Statistical analysis
Willcoxon 2 sample testing was used to determine the
significance of the differences between two groups of skewness
distribution data, and P,0.05 was considered significant. For
more than three distribution measurement data groups, we used
SNK grouping (q testing) and Kruskal-Wallis testing. All of the
above analyses were performed using the statistical software SAS
8.0 for Windows. ROC curves were built using SPSS 13.0 for
Windows.
Supporting Information
Figure S1 LC-MS/MS identification of selected spots. A.
Mowse score of spot 1. B. Sequence coverage of peptides to
SPON2 (Matched peptides shown in Bold). C. Sequence coverage
of peptides to THBS-1 (Matched peptides shown in Bold). D.
Sequence coverage of peptides to TPI1 (Matched peptides shown
in Bold). E. Sequence coverage of peptides to PGAM1 (Matched
peptides shown in Bold). F. Mowse score of spot 2. G. Sequence
coverage of peptides to ST1 (Matched peptides shown in Bold). H.
Mowse score of spot 3. I. Sequence coverage of peptides to TPI1
(Matched peptides shown in Bold). J. Mowse score of spot 4. K.
Sequence coverage of peptides to PRDX1 (Matched peptides
shown in Bold). L. Mowse score of spot 5. M. Sequence coverage
of peptides to NPM1 (Matched peptides shown in Bold).
(TIF)
Table S1 Details of human prostate tissue microarray
used in this research paper including SPON2 IOD sum
we calculated.
(DOC)
Table S2 Details of PCa patients and normal aged men
used in this research paper including serum SPON2
level we calculated.
(DOC)
Table S3 Primers for Semi-Quantitative RT-PCR.
(DOC)
Text S1 Protocols for In gel digestion, LC-MS/MS and
Data base querying.
(DOC)
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